Get the app
US › Healthcare

Molecular Partners AG ADR (MOLN)

US · Healthcare · Biotechnology

$3.56-2.47%
Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue
$0
Net profit
$-13.5M
EPS
$-0.44
EPS estimate
$-0.45

EPS came in at -0.44 against a street estimate of -0.45 — a beat of 2.2%.

Key statistics

Market cap
$136.4M
Forward P/E
1.7
P/B
2.31
Book value
$1.85
EPS (TTM)
$-1.76
52-week high
$5.36
52-week low
$3.52
50-day MA
$4.12
200-day MA
$4.20
Beta
0.69

Analyst view

Analysts rate Molecular Partners AG ADR a strong buy (4 buy, 1 hold, 0 sell out of 5) with an average price target of $10.36.

Shareholding

Institutions
9.38%

Largest institutional holders

FundStake
Suvretta Capital Management, LLC5.80%
Bvf Inc3.53%
Citadel Advisors Llc0.04%
Morgan Stanley - Brokerage Accounts0.00%
UBS Group AG0.00%
EverSource Wealth Advisors, LLC0.00%
SmartHarvest Portfolios, LLC0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Molecular Partners AG ADR — free to start.

Open in the appGoogle PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncAmgen IncGilead Sciences IncAbbott LaboratoriesNovo Nordisk A/S

Data updated 2026-10-18.